Categories AlphaGraphs, Health Care, U.S. Markets News

Allergan, Mylan and other generics beam as Pfizer loses patent war in the UK

It was good news for generic drug firms such as Allergan (AGN) and Mylan (MYL), as pharma giant Pfizer (PFE) lost a long legal battle in Britain regarding the patents surrounding its hit drug Lyrica.

Pain drug Lyrica — generically: pregabalin — rakes in about $5 billion a year for the drugmaker, and the UK apex court ruled against Pfizer affirming a secondary medical use for the medication.

Years of legal bouts in lower courts finally ended with a defeat, and it is more significant now that the secondary pain patent has expired in Europe.

Pfizer, expressing disappointment at the ruling, said that the outcome was a huge blow to medical innovation incentives.

Pfizer third quarter 2018 Earnings Infographic

Pfizer argued that generic drug companies such as Actavis (now, Allergen) and Mylan would be subject to patent infringement on the second patent, despite skinny labeling (generic products labeled only as suitable for treatment of epilepsy and GAD.)

The Supreme Court said it saw Pfizer claims failing “for insufficiency” and overruled the patent plea.

In a gist, the ruling suggests that the patent protection for manufacturing pregabalin — to treat peripheral and central neuropathic pain — was removed.

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Tyson Foods (TSN) Q1 2023 Earnings: Key financials and quarterly highlights

Tyson Foods Inc. (NYSE: TSN) reported first quarter 2023 earnings results today. Sales rose 2.5% year-over-year to $13.2 billion. Net income attributable to Tyson was $316 million, or $0.88 per

After weak start to 2023, Apple (AAPL) sees some bright spots

Apple Inc. (NASDAQ: AAPL) this week reported its first revenue decline in more than three years, even as the high inflation continues to squeeze customers’ spending power. Sales of the

Earnings: Qualcomm (QCOM) Q1 profit falls on lower revenues

Chipmaker Qualcomm, Inc. (NASDAQ: QCOM) has reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for the second quarter of 2023. At $9.5

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top